Cell therapy could unlock next cancer revolution for AstraZeneca
In this week’s Executive Interview, we speak with Mark Cobbold, vice president discovery and head of Cell Therapy, Oncology R&D, at AstraZeneca, and Carsten Linnemann, chief executive officer of Neogene Therapeutics, part of AstraZeneca.
This article has been commissioned and funded by AstraZeneca.
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. Over recent years there has been huge investment and growth in cell therapies, but success beyond blood cancers has so far been limited.
AstraZeneca is on a mission to change this and is steadily building their expertise and capabilities with the aim of bringing the transformative potential of T cell therapies to more patients living with cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze